BBTV

About Us

latest videos

Paion AG CEO Wolfgang Soehngen Interviewed by Swati Kumar

Wall Street on BioBusiness.TV
  1. Batman is Back, Busting Clots with Desmotoplase
  2. Paion De-Risks Pipeline with Acquisition of New Value Driver CNS 7056
  3. IPaion’s Search & Develop Strategy: Get the Proof of Concept Faster and Cheaper than Pharma

Addex CEO Vincent Mutel Interviewed by Ram Selvaraju

Wall Street on BioBusiness.TV
  1. Dim That Receptor Activity with Addex’s Allosteric Modulation
  2. Addex’s New Lead Molecule ADX48621, Expected To Be Partnered Soon?
  3. December 2009, A Major Setback for Addex. Use of Cash, and Other Pipeline Molecules
  4. ADDEX Undervalued? What Could Drive Stock Price In The Next 6 Months

Osteoporosis Breakthrough, Professor Gerard Karsenty

Nature Medicine and BioBusiness.TV present Science Breakthrough
  1. Major Breakthrough in $5bn Osteoporosis Market
  2. Inhibiting Serotonin Synthesis in the Gut, Rationale for Treating Osteoporosis
  3. How Does an Anabolic Treatment Compare to Other Approaches in Development for Osteoporosis?
  4. Study of Rare Genetic Disease Leads to New Target for the Treatment of Most Common Bone Disease

2010 JP Morgan Healthcare Conference Report

  1. Who is Investing in Biotech Today? Kris Jenner
  2. Reconsidering Small and Mid Caps, IPOs, and Value Drivers. Kris Jenner
  3. Shareholder Activism in 2010, Good or Bad? Kris Jenner
  4. 2010 JP Morgan Healthcare Conference, the Insider Perspective
  5. Key Issues for Venture Capital Invetments and Fund Raising. Ansbert Gadicke
  6. Pharma Opportunities, Novel Technologies, and Diseases of the Decade. Ansbert Gadicke
  7. The Insider Perspective, with Geoff Meacham (Part 1)
  8. The Insider Perspective, with Geoff Meacham (Part 2)

YM BioSciences, 60sec

YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization. The Company is currently ...

Paion, 60sec

PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specializing in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which ...

Epigenomics, 60sec

Cancer is a dreaded and often fatal disease. However, given today’s treatment options, outcomes could potentially be greatly improved if more cancers were detected in early stages and treatments were better tailored to individual patients’ needs. This widely unmet medical need makes IVD (in vitro diagnostic) tests for cancer a segment with high future growth ...

Oxford BioMedica, 60sec

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative treatments to improve the lives of patients with high unmet medical needs. Our mission is to build a top-tier profitable biopharmaceutical company founded on the successful development and commercialisation of novel gene-based medicines. Oxford BioMedica has established a platform of technologies in gene delivery and immunotherapy, protected ...

Wilex, 60sec

WILEX is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. The Company was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX’s mission is to develop drugs with a low side effect profile and targeted ...

Magforce, 60sec

MagForce Nanotechnologies AG is the global leader in the field of nanotechnology cancer treatment. This revolutionary technology aims to establish a entirely new form of cancer treatment within the near future, using magnetic particles to treat tumors with very minimal side effects, thus enhancing patient quality of life. The technology and its related equipment are ...

<< Previous12345678910Next >>...Last »

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs

  • Acknowlegments

    NASDAQ OMX BIO Nature Medicine William Blair Banc of America Cowen Group JMP Securities JP Morgan Ladenburg Thalmann Lazard Capital Markets Piper Jaffrey

  • About the Pitches


    Less is More. In 60 seconds, get the pitch and meet the team.

    If you would like to submit your own 60sec company pitch, submit it to : 60sec [at] biobusiness.tv

  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved